Insights
At SSI Strategy, we believe that knowledge is a key driver in building better biotechs. Our Insights provide valuable information and expert perspectives to empower biotech leaders like you.
Insights
04-02-2026
EU HTA Regulation: Early Signals, Open Questions, and Practical Choices for Biotechs
In our fifth and final webinar on the new EU HTA Regulation, Chantal van Gils and Mel Walker will reflect on how the regulation is beginning to play out in practice for small and mid-size biotech teams preparing for EU market access.
02-02-2026
What the EU HTA Regulation Means for Biotechs
With Joint Clinical Assessment (JCA), “EMA-ready” won’t always mean “HTA-ready.” Learn what the EU HTA Regulation changes for biotechs—and how to prepare for PICO scoping, comparator expectations, and compressed dossier timelines.
01-02-2026
How the EU HTA Reform Will Change Trial Design
EU HTA readiness is an operating model shift—not a market access add-on. This post explains how to align teams and governance early for parallel MAA + JCA execution.
09-05-2025
EU HTA Regulation: Joint Scientific Consultation – Key Steps, Timing & Strategy
Join our experts Chantal W.M. van Gils & Sigrid Klaar on Thursday, 5th June at 14:00 BST | 15:00 CEST | 09:00 EDT for the fourth installment of our webinar series on the European Health Technology Assessment (HTA) regulation.
21-01-2025
EU HTA Regulation: JCA in Practice – From Procedure to Evidence Generation
Join our experts Chantal W.M. van Gils & Sigrid Klaar on Thursday, 23rd January at 14:00 UK | 15:00 CET | 09:00 EST for the third installment of our webinar series on the European Health Technology Assessment (HTA) regulation.
LET'S TALK
You don't have to go it alone!
Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.
Building Better Biotechs
